The CAR T-cell therapy pipeline has experienced significant growth, with over 180 companies actively developing more than 200 innovative cell therapy candidates across various stages of clinical development.
KIMMTRAK achieved $310 million in net sales for 2024, with $84.1 million in Q4, marking 11 consecutive quarters of growth and launches in 14 new territories.
Bristol Myers Squibb's Opdivo/Yervoy combo demonstrated superior overall survival in first-line unresectable hepatocellular carcinoma compared to Lenvima or Nexavar.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.